Page last updated: 2024-08-24

tirofiban and Hypertension

tirofiban has been researched along with Hypertension in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davakhar, S; Hiremath, S; Krishna, K; Lakade, S	1
Bae, HJ; Chung, JW; Han, MK; Jang, MS; Jung, C; Kim, JH; Kim, KJ; Kwon, OK; Lee, J; Lee, JS; Noh, WY; Oh, CW; Yang, MH	1
Chamorro, A; Díez-Marqués, ML; Griera, M; Rodríguez-Puyol, D; Rodríguez-Puyol, M; Ruiz-Torres, MP	1
Cam, N; Okmen, E; Ozen, E; Sanli, A; Tartan, Z; Uyarel, H	1

Trials

1 trial(s) available for tirofiban and Hypertension

Article	Year
Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor. Japanese heart journal, 2003, Volume: 44, Issue:6 Topics: Aged; Angina, Unstable; Anticoagulants; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Nadroparin; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk; Tirofiban; Treatment Outcome; Tyrosine	2003

Article

Year

Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor.

Japanese heart journal, 2003, Volume: 44, Issue:6

Topics: Aged; Angina, Unstable; Anticoagulants; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Nadroparin; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk; Tirofiban; Treatment Outcome; Tyrosine

2003

Other Studies

3 other study(ies) available for tirofiban and Hypertension

Article	Year
Acute Myocardial Infarction in Nephrotic Syndrome. The Journal of the Association of Physicians of India, 2015, Volume: 63, Issue:11 Topics: Adult; Anterior Wall Myocardial Infarction; Coronary Angiography; Coronary Vessels; Fibrinolytic Agents; Humans; Hypertension; Injections, Intra-Arterial; Male; Nephrotic Syndrome; Nitroglycerin; ST Elevation Myocardial Infarction; Thrombectomy; Tirofiban; Treatment Outcome; Tyrosine; Vasodilator Agents	2015
Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator. Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 35, Issue:5 Topics: Abciximab; Aged; Antibodies, Monoclonal; Atrial Fibrillation; Brain Ischemia; Combined Modality Therapy; Comorbidity; Female; Fibrinolytic Agents; Humans; Hypertension; Immunoglobulin Fab Fragments; Infusions, Intra-Arterial; Infusions, Intravenous; Intracranial Hemorrhages; Magnetic Resonance Imaging; Male; Mechanical Thrombolysis; Middle Aged; Neuroimaging; Prognosis; Registries; Retrospective Studies; Risk Factors; Severity of Illness Index; Single-Blind Method; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Treatment Outcome; Tyrosine; Urokinase-Type Plasminogen Activator	2013
Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences. Cardiovascular research, 2009, Apr-01, Volume: 82, Issue:1 Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Guanylate Cyclase; Humans; Hypertension; Isosorbide Dinitrate; Male; Muscle, Smooth, Vascular; Nitric Oxide Donors; Nitroprusside; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Tachyphylaxis; Time Factors; Tirofiban; Tyrosine; Up-Regulation; Vasodilation; Vasodilator Agents	2009